Secondary IGF-I Deficiency as a Prognostic Factor of Growth Hormone (GH) Therapy Effectiveness in Children with Isolated, Non-acquired GH Deficiency

Smyczyńska, Joanna; Stawerska, Renata; Hilczer, Maciej; Lewiński, Andrzej

doi:10.1055/s-0034-1395665

Cited by 4 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, IGF1 was classified as normal or low based on the reference range provided by each centre. Previous predictive models demonstrated a negative correlation between IGF1 SDS and height gain [17,23,30,31]. Similarly, in our study patients with low pre-treatment IGF1 presented a larger height gain than the other ones.…”

Section: Discussionsupporting

confidence: 86%

Isolated childhood growth hormone deficiency: a 30-year experience on final height and a new prediction model

Lonero

Giotta

Guerrini

et al. 2022

J Endocrinol Invest

View full text Add to dashboard Cite

Purpose We aimed to evaluate the near-final height (nFHt) in a large cohort of pediatricpatients with growth hormone deficiency (GHD) and to elaborate a new predictive method of nFHt. Methods We recruited GHD patients diagnosed between 1987 and 2014 and followed-up until nFHt. To predict the values of nFHt, each predictor was run in a univariable spline. ResultsWe enrolled 1051 patients. Pre-treatment height was −2.43 SDS, lower than parental height (THt) (−1.09 SDS, p < 0.001). The dose of recombinant human GH (rhGH) was 0.21mg/kg/week at start of treatment. nFHt was −1.08 SDS (height gain 1.27 SDS), higher than pre-treatment height (p < 0.001) and comparable to THt. 1.6% of the patients were shorter than −2 SDS from THt. The rhGH dose at nFHt was 0.19 mg/kg/week, lower than at the start (p < 0.001). The polynomial regression showed that nFHt was affected by gender, THt, age at puberty, height at puberty, age at the end of treatment (F = 325.37, p < 0.0001, R 2 87.2%). Conclusion This large national study shows that GHD children can reach their THt. The rhGH/kg/day dose significantly decreased from the start to the end of the treatment. Our model suggests the importance of a timely diagnosis, possibly before puberty, the beneficial effect of long-term treatment with rhGH, and the key-role of THt. Our prediction model has a very acceptable error compared to the majority of other published studies.

show abstract

Section: Discussionsupporting

confidence: 86%

Isolated childhood growth hormone deficiency: a 30-year experience on final height and a new prediction model

Lonero

Giotta

Guerrini

et al. 2022

J Endocrinol Invest

View full text Add to dashboard Cite

show abstract

“…Research on GH axis in a particular and sometimes complicated category of subjects represented by T1D is growing [31][32][33] In conclusion, our study has 3 major findings. First, GH/IGF-I axis parameters are similar with detemir and glargine insulin in prepubertal children.…”

Section: Discussion ▼mentioning

confidence: 57%

Long-acting Insulin Analogs Effect on gh/igf Axis of Children with Type 1 Diabetes: a Randomized, Open-label, Two-period, Cross-over Trial

Cherubini

Pintaudi

Iannilli

et al. 2016

Exp Clin Endocrinol Diabetes

View full text Add to dashboard Cite

show abstract

“…A further use could be hypothesized for the diagnosis of GH deficiency. It is of interest that the value of the information contained in the three miRNA levels and their early variation in predicting growth was greater than that contained in IGF-I serum levels ( 43 , 44 ), suggesting that miRNAs could effectively be of value for further research.…”

Section: Discussionmentioning

confidence: 99%

Specific miRNAs Change After 3 Months of GH treatment and Contribute to Explain the Growth Response After 12 Months

et al. 2022

View full text Add to dashboard Cite

ContextThere is growing evidence of the role of epigenetic regulation of growth, and miRNAs potentially play a role.ObjectiveThe aim of this study is to identify changes in circulating miRNAs following GH treatment in subjects with isolated idiopathic GH deficiency (IIGHD) after the first 3 months of treatment, and verify whether these early changes can predict growth response.Design and MethodsThe expression profiles of 384 miRNAs were analyzed in serum in 10 prepubertal patients with IIGHD (5 M, 5 F) at two time points before starting GH treatment (t−3, t0), and at 3 months on treatment (t+3). MiRNAs with a fold change (FC) >+1.5 or <-1.5 at t+3 were considered as differentially expressed. In silico analysis of target genes and pathways led to a validation step on 8 miRNAs in 25 patients. Clinical and biochemical parameters were collected at baseline, and at 6 and 12 months. Simple linear regression analysis and multiple stepwise linear regression models were used to explain the growth response.ResultsSixteen miRNAs were upregulated and 2 were downregulated at t+3 months. MiR-199a-5p (p = 0.020), miR-335-5p (p = 0.001), and miR-494-3p (p = 0.026) were confirmed to be upregulated at t+3. Changes were independent of GH peak values at testing, and levels stabilized after 12 months. The predicted growth response at 12 months was considerably improved compared with models using the common clinical and biochemical parameters.ConclusionsMiR-199a-5p, miR-335-5p, and miR-494-3p changed after 3 months of GH treatment and likely reflected both the degree of GH deficiency and the sensitivity to treatment. Furthermore, they were of considerable importance to predict growth response.

show abstract

Secondary IGF-I Deficiency as a Prognostic Factor of Growth Hormone (GH) Therapy Effectiveness in Children with Isolated, Non-acquired GH Deficiency

Abstract: In children with isolated, non-acquired GHD, secondary IGF-I deficiency is an important predictor of better GH therapy effectiveness.

Cited by 4 publications

References 22 publications

Isolated childhood growth hormone deficiency: a 30-year experience on final height and a new prediction model

Isolated childhood growth hormone deficiency: a 30-year experience on final height and a new prediction model

Long-acting Insulin Analogs Effect on gh/igf Axis of Children with Type 1 Diabetes: a Randomized, Open-label, Two-period, Cross-over Trial

Specific miRNAs Change After 3 Months of GH treatment and Contribute to Explain the Growth Response After 12 Months

Contact Info

Product

Resources

About